Effect of dexamethasone in hospitalized patients with COVID-19–preliminary report

…, C Green, T Felton, D Chadwick, K Rege, C Fegan… - MedRxiv, 2020 - medrxiv.org
Background Coronavirus disease 2019 (COVID-19) is associated with diffuse lung damage.
Corticosteroids may modulate immune-mediated lung injury and reducing progression to …

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

…, A Haynes, J Tighe, D Oscier, C Fegan… - Journal of Clinical …, 2005 - ascopubs.org
Purpose To test whether eradication of minimal residual disease (MRD) in B-cell chronic
lymphocytic leukemia (CLL) by alemtuzumab is associated with a prolongation of treatment-free …

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

…, H Waldmann, G Hale, CD Fegan… - Blood, The Journal …, 2002 - ashpublications.org
Nonmyeloablative conditioning is increasingly used for transplantation in a wide range of
diseases, but little is known about its impact on the incidence of infections and immune …

Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL

…, L Hooper, J Starczynski, AMR Taylor, C Fegan… - Blood, 2005 - ashpublications.org
The ataxia telangiectasia mutated (ATM) protein is the principal activator of the p53 protein
in the response to DNA double-strand breaks. Mutations in the ATM gene have been …

South Asian chronic lymphocytic leukaemia patients have more rapid disease progression in comparison to White patients

…, B Austen, JE Powell, C Fegan… - British journal of …, 2008 - Wiley Online Library
Ethnicity has a major impact on the prevalence of chronic lymphocytic leukaemia (CLL) and
may also influence disease phenotype. We compared the clinical features of Southern Asian …

[HTML][HTML] Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study

…, R Boucher, D MacDonald, C Fegan… - Journal of clinical …, 2019 - ncbi.nlm.nih.gov
PURPOSE The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by
targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (…

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

…, G Cartron, F Morschhauser, C Fegan… - Blood, The Journal …, 2016 - ashpublications.org
We report the results of a multicenter phase 1 dose-escalation study of the selective Bruton
tyrosine kinase (BTK) inhibitor ONO/GS-4059 in 90 patients with relapsed/refractory B-cell …

Dexamethasone in hospitalized patients with Covid-19-preliminary report

…, T Felton, D Chadwick, K Rege, C Fegan… - The New England …, 2020 - kclpure.kcl.ac.uk
Background: Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage.
Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce …

Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers

…, L Hooper, T Stankovic, C Fegan - Blood, The Journal …, 2008 - ashpublications.org
Bcl-2 family proteins play a critical role in the regulation of apoptosis in chronic lymphocytic
leukemia (CLL). However, their association with established prognostic markers is unknown. …

Potential role of oral rinses targeting the viral lipid envelope in SARS-CoV-2 infection

…, SA Jones, I Humphreys, MJO Wakelam, C Fegan… - Function, 2020 - academic.oup.com
Emerging studies increasingly demonstrate the importance of the throat and salivary glands
as sites of virus replication and transmission in early COVID-19 disease. SARS-CoV-2 is an …